Related Experiment Video
Updated: Apr 17, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
Joyce M van Dodewaard-de Jong1, Henk M W Verheul1, Haiko J Bloemendal2
1Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Abstract:
Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.
Insights
Systemic treatments for metastatic prostate cancer are advancing. This review details current options and proposes optimal sequencing for therapies like docetaxel and abiraterone to improve patient survival.
Area of Science:
- Oncology
- Urology
Background:
- Systemic treatment for metastatic prostate cancer is evolving rapidly.
- Androgen deprivation therapy is the standard first-line treatment.
- New therapeutic strategies have emerged for castration-resistant prostate cancer.
Purpose of the Study:
- To provide an overview of current systemic treatment options for metastatic prostate cancer.
- To propose considerations for optimally sequencing new therapies.
- To hypothesize on combination strategies for improved outcomes.
Main Methods:
- Review of current systemic treatment options.
- Analysis of large clinical trials.
- Discussion of therapeutic sequencing and combination strategies.
Main Results:
- Docetaxel improves survival in extensive metastatic disease.
- Sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, and radium-223 offer survival benefits.
- Sequencing of these therapies is a critical consideration.
Conclusions:
- Optimal sequencing of novel therapies is crucial for maximizing survival benefits.
- Combination strategies may further enhance treatment outcomes.
- This review offers guidance for managing advanced prostate cancer.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...